This site is intended only for healthcare professionals resident in the United Kingdom
IBRANCE is indicated for the treatment of HR+/HER2-, locally advanced or mBC in combination with an AI or with fulvestrant in women who have received prior ET. In pre-and peri-menopausal women, the ET should be combined with a LHRH agonist.
Mark Verrill Case Study Videos
IBRANCE® treatment case study videos across a variety of patient groups.
Duration:
03:20 - 08:06
IBRANCE® case study videos by Mark Verrill (Head of Medical Oncology and Deputy Lead Clinician for Breast Cancer North of England Cancer Network) discussing the use of IBRANCE® in the following patient groups.
- Elderly patient with bone metastasis
- Pre-menopausal patient
- Second line patient
- Patient with significant visceral metastasis
Speaker
IBRANCE® case study video of an elderly patient with bone metastasis
IBRANCE® case study video of a pre-menopausal patient.
IBRANCE® case study video of a second line patient.
IBRANCE® case study video of a patient with significant visceral metastasis.
PP-IBR-GBR-3179. January 2021